Eton Pharmaceuticals (ETON) awards 128,985 performance RSUs to executive
Rhea-AI Filing Summary
Eton Pharmaceuticals, Inc. reported that Chief Business Officer David Krempa received a grant of 128,985 performance-vested restricted stock units on July 31, 2026 under the 2018 equity incentive plan. Each unit may convert into one share of common stock if the closing price reaches $72.36 per share for one trading day before the third anniversary of the grant; otherwise the entire award is forfeited without consideration on July 31, 2029. The 128,985 units represent the maximum and only number of shares issuable under this award.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Krempa David
Role
Chief Business Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock F1 | 128,985 | $0.00 | $0.00 |
Holdings After Transaction:
Common Stock — 128,985 shares (Direct)
Footnotes (1)
- F1. On July 31, 2026, the reporting person was granted 128,985 performance-vested restricted stock units granted under the Issuer's 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of Issuer common stock. The award vests in full, and all restrictions lapse, immediately upon the closing price of the Issuer's common stock equaling or exceeding $72.36 per share for one trading day at any time prior to the third anniversary of the grant date. If this market condition is not satisfied prior to such date, the award will be forfeited in its entirety without consideration on July 31, 2029.The number of shares reported reflects the maximum and only number of shares issuable under the award; there is no target, threshold, or maximum range.
Key Figures
RSUs granted: 128,985 units
Grant price: $0.0000 per unit
Vesting share price condition: $72.36 per share
+2 more
5 metrics
RSUs granted
128,985 units
Performance-vested restricted stock units granted July 31, 2026 to Chief Business Officer
Grant price
$0.0000 per unit
Stated transaction price per share for the RSU grant
Vesting share price condition
$72.36 per share
Closing price required for one trading day for the award to vest in full
Forfeiture date
July 31, 2029
Date the award is forfeited without consideration if the market condition is not met
Holdings after grant
128,985 units
Reported total related holdings following the RSU grant
Key Terms
restricted stock units, equity incentive plan, performance-vested, closing price
4 terms
restricted stock units financial
"the reporting person was granted 128,985 performance-vested restricted stock units granted under"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
equity incentive plan financial
"restricted stock units granted under the Issuer's 2018 equity incentive plan"
An equity incentive plan is a program that gives employees, executives or directors the right to receive company stock or options to buy stock as part of their pay. Think of it as offering slices of future company profit to motivate people to boost long‑term performance; for investors it matters because it can align employee goals with shareholder value but also increases the number of shares outstanding, which can dilute existing ownership.
performance-vested financial
"was granted 128,985 performance-vested restricted stock units granted under"
An award or right—often shares or stock options—that becomes owned by an employee only after the company meets specific performance goals, such as revenue, profit, or stock-price targets. Investors care because performance-vested awards tie management pay to company results, which can encourage behavior that improves value but also affects future share count and reported expenses depending on whether targets are met; think of it like a bonus that only unlocks when clearly defined goals are hit.
closing price financial
"upon the closing price of the Issuer's common stock equaling or exceeding $72.36"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did ETON report for David Krempa?
Eton Pharmaceuticals reported that Chief Business Officer David Krempa received 128,985 performance-vested restricted stock units on July 31, 2026. These units were granted under the company’s 2018 equity incentive plan and each can convert into one share of common stock if the performance condition is met.
How many RSUs were granted to ETON executive David Krempa and at what price?
David Krempa was granted 128,985 restricted stock units tied to Eton Pharmaceuticals common stock. The Form 4 lists a transaction price of $0.0000 per unit, reflecting a compensation grant rather than a market purchase, with conversion into shares dependent on a specified stock-price condition.
What performance condition applies to David Krempa’s ETON RSU award?
The RSU award vests in full only if Eton Pharmaceuticals’ common stock closing price equals or exceeds $72.36 per share for one trading day before the third anniversary of the July 31, 2026 grant. If this market condition is not met, the entire award is forfeited.
When will David Krempa’s ETON RSUs be forfeited if they do not vest?
If the stock-price condition is not satisfied by the third anniversary of the July 31, 2026 grant, the entire 128,985-unit award will be forfeited without consideration on July 31, 2029. No shares will be issued to David Krempa if forfeiture occurs.
Under which plan were the ETON RSUs for David Krempa granted?
The 128,985 performance-vested RSUs granted to David Krempa were issued under Eton Pharmaceuticals’ 2018 equity incentive plan. Each restricted stock unit represents the right to acquire one share of the company’s common stock if the specified market condition is achieved.